In 19521 first heard about a drug from France which had remarkable properties in treating psychotic patients. It had just become available in the United States, a transplant via Canada from Rhone Poulenc of France. The Canadian representative tried to peddle it to United States companies starting from the largest and working his way down to the least significant. He was rejected by all the companies with the exception of the last, a one product company whose medical director had the vision to realize the importance of this product. What was known as Chlorpromazine in Canada became thorazine in the United States. That company today is one of the largest.